[
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-1603",
    "desc": "A randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of ARGX-113 in patients with newly diagnosed Immune Thrombocytopenia",
    "year": "2016",
    "status": "completed",
    "new_desc": "A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia, followed by an Open-Label Treatment Period",
    "new_year": "2016",
    "new_status": "completed"
  },
  {
    "diffs": "S",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-1705",
    "desc": "A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of\r\nARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness (ADAPT+)",
    "year": "2017",
    "status": "ongoing",
    "new_desc": "A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of\r\nARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness (ADAPT+)",
    "new_year": "2017",
    "new_status": "completed"
  },
  {
    "diffs": "S",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-1802",
    "desc": "A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)",
    "year": "2018",
    "status": "ongoing",
    "new_desc": "A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)",
    "new_year": "2018",
    "new_status": "completed"
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2006",
    "desc": "MG pediatric study",
    "year": "2020",
    "status": "ongoing",
    "new_desc": "Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",
    "new_year": "2020",
    "new_status": "ongoing"
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2007",
    "desc": "A Phase2/3 trial in subgroup(s) (tbd which subgroups) of myositis",
    "year": "2020",
    "status": "ongoing",
    "new_desc": "A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",
    "new_year": "2020",
    "new_status": "ongoing"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2008",
    "desc": "OL extension study to 113-2006 MG pediatric study",
    "year": "2020",
    "status": "startup",
    "new_desc": "A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis",
    "new_year": "2020",
    "new_status": "ongoing"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2010",
    "desc": "Ph2/3 OLE study to 113-2009 BP",
    "year": "2020",
    "status": "startup",
    "new_desc": "An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",
    "new_year": "2020",
    "new_status": "ongoing"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2011",
    "desc": "OLE to 113-2007 Myositis",
    "year": "2020",
    "status": "planning",
    "new_desc": "A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",
    "new_year": "2020",
    "new_status": "ongoing"
  },
  {
    "diffs": "S",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2105",
    "desc": "An Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104",
    "year": "2021",
    "status": "startup",
    "new_desc": "An Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104",
    "new_year": "2021",
    "new_status": "ongoing"
  },
  {
    "diffs": "S",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2106",
    "desc": "A Phase 2, Randomized, Placebo-Controlled, Parallel-Group, Double-Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren’s Syndrome",
    "year": "2021",
    "status": "startup",
    "new_desc": "A Phase 2, Randomized, Placebo-Controlled, Parallel-Group, Double-Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren’s Syndrome",
    "new_year": "2021",
    "new_status": "ongoing"
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2201",
    "desc": "A Phase 1, Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10 mg/kg Single Dose Administered in Participants With Renal Impairment",
    "year": "2022",
    "status": "startup",
    "new_desc": "A Phase 1, Open-label, Study to Evaluate the Pharmacokinetics of Efgartigimod IV 10 mg/kg Single Dose Administered in Participants With Renal Impairment",
    "new_year": "2022",
    "new_status": "startup"
  },
  {
    "diffs": "S",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2204",
    "desc": "A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Vial-Syringe Presentation in Healthy Adults",
    "year": "2022",
    "status": "planning",
    "new_desc": "A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered via a Prefilled Syringe Versus a Vial-Syringe Presentation in Healthy Adults",
    "new_year": "2022",
    "new_status": "ongoing"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2207",
    "desc": "MG SC pediatric study",
    "year": "2022",
    "status": "planning",
    "new_desc": "An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",
    "new_year": "2022",
    "new_status": "startup"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2301",
    "desc": "A phase 3, multicenter, randomized,  double-blinded, placebo-controlled  study evaluating Efgartigimod  PH20 SC administered by prefilled syringe (PFS) treatment in patients with moderate-to-severe active Thyroid Eye Disease (TED)",
    "year": "2023",
    "status": "planning",
    "new_desc": "A Phase 3, Randomized,  Double-blinded, Placebo-Controlled,  Multicenter  Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod  PH20 SC administered by prefilled syringe (PFS)  in Adult Participants With Active Thyroid Eye Disease",
    "new_year": "2023",
    "new_status": "startup"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2302",
    "desc": "Antibody Mediated Rejection (AMR)",
    "year": "2023",
    "status": "planning",
    "new_desc": "A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Tolerability and Safety of Efgartigimod in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients",
    "new_year": "2023",
    "new_status": "startup"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2309",
    "desc": "TED phase 3 main study",
    "year": "2023",
    "status": "planning",
    "new_desc": "A Phase 3, Randomized,  Double-blinded, Placebo-Controlled,  Multicenter  Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod  PH20 SC administered by prefilled syringe (PFS)  in Adult Participants With Active Thyroid Eye Disease",
    "new_year": "2023",
    "new_status": "startup"
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-2310",
    "desc": "TED OLE study",
    "year": "2023",
    "status": "planning",
    "new_desc": "An Open-Label Extension, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in adult participants with Thyroid Eye Disease (TED)",
    "new_year": "2023",
    "new_status": "planning"
  },
  {
    "diffs": "DYS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-113-NIS-2313",
    "desc": "",
    "year": "",
    "status": "",
    "new_desc": "An International, Longitudinal, Prospective, Observational Registry of Adult Patients With PV and PF to Evaluate the Clinical, Humanistic, and Economic Burden of the Disease and Treatment Patterns",
    "new_year": "2023",
    "new_status": "planning"
  },
  {
    "diffs": "S",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-117-1901",
    "desc": "A First-In-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous and Subcutaneous Doses of ARGX-117",
    "year": "2019",
    "status": "ongoing",
    "new_desc": "A First-In-Human, Randomized, Double-Blinded, Placebo-Controlled Trial in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous and Subcutaneous Doses of ARGX-117",
    "new_year": "2019",
    "new_status": "completed"
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-117-2201",
    "desc": "A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-\r\nControlled Study to Assess the Efficacy and Safety of ARGX-117 in Preventing Delayed\r\nGraft Function and Improving Short Term and Long Term Allograft Function in Recipients\r\nof a Renal Allograft From High-Risk, Deceased Donor Transplants",
    "year": "2022",
    "status": "startup",
    "new_desc": "A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-\r\nControlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function",
    "new_year": "2022",
    "new_status": "startup"
  },
  {
    "diffs": "DS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-117-2202",
    "desc": "natural history study in MMN",
    "year": "2022",
    "status": "planning",
    "new_desc": "A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health- Related Quality of Life, and Health Care Resource Utilization in Adult Patients with Multifocal Motor Neuropathy",
    "new_year": "2022",
    "new_status": "startup"
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-119-2201",
    "desc": "A First-in-Human, Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Subjects to Investigator the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single and Multiple Ascending Intravenous Dose Levels of ARGX-119.",
    "year": "2022",
    "status": "ongoing",
    "new_desc": "A Phase 1, Randomized, Double Blinded, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX 119 in Healthy Participants",
    "new_year": "2022",
    "new_status": "ongoing"
  },
  {
    "diffs": "DYS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-119-2301",
    "desc": "A Pre-Screening and Recruitment Study in Adults with DOK7- Congenital Myasthenic Syndrome Expressing Interest in a Later Phase 1b Study",
    "year": "2023",
    "status": "planning",
    "new_desc": "",
    "new_year": "",
    "new_status": ""
  },
  {
    "diffs": "D",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-119-2302",
    "desc": "A Phase 1b Double Blinded Randomized Controlled Study of ARGX-119 in Patients with DOK7-Congenital Myasthenic Syndrome",
    "year": "2023",
    "status": "planning",
    "new_desc": "A phase 1b, randomized, double-blinded, placebo-controlled study of ARGX -119 in participants with DOK7-congenital myasthenic syndromes",
    "new_year": "2023",
    "new_status": "planning"
  },
  {
    "diffs": "DYS",
    "previous": "2023-08-18",
    "latest": "2023-09-15",
    "study": "ARGX-119-NIS-2301",
    "desc": "",
    "year": "",
    "status": "",
    "new_desc": "Multicenter, Multinational Natural History Study for Participants with DOK7-Congenital Myasthenic Syndrome",
    "new_year": "2023",
    "new_status": "planning"
  }
]
